Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
← catalyst calendarSponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
64actual
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-14 | actual | When the study began enrolling |
| Primary completion | 2025-06-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-20 | actual | The whole study's end, after follow-up |
| First posted | 2021-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplantation in Highly Sensitized Patients
Interventions
- Drug: Imlifidase — also filed as IdeS, HMED-IdeS
- Procedure: PLEX — also filed as Plasma exchange, PE
- Drug: IVIg — also filed as Intravenous immunoglobulin
- Drug: Anti-CD20 antibodies — also filed as Rituximab
- Drug: Eculizumab — also filed as Soliris
- Other: Remain on wait list
Primary outcome
what the primary-completion date above is the date OFMean estimated glomerular filtration rate (eGFR) at 12 months
measured 12 months after randomization
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed